Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Sells $16,610.88 in Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) insider Mo Qatanani sold 1,936 shares of Scholar Rock stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $8.58, for a total value of $16,610.88. Following the transaction, the insider now directly owns 142,768 shares in the company, valued at $1,224,949.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Scholar Rock Stock Performance

Shares of Scholar Rock stock opened at $8.27 on Thursday. The stock has a 50 day moving average price of $8.94 and a 200-day moving average price of $11.32. Scholar Rock Holding Co. has a one year low of $6.03 and a one year high of $21.17. The company has a current ratio of 6.04, a quick ratio of 6.04 and a debt-to-equity ratio of 0.36.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.01. During the same quarter in the prior year, the company earned ($0.47) EPS. Equities analysts forecast that Scholar Rock Holding Co. will post -2.39 EPS for the current year.

Institutional Trading of Scholar Rock

A number of large investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD lifted its holdings in Scholar Rock by 16.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,321,471 shares of the company’s stock valued at $156,444,000 after buying an additional 1,149,519 shares in the last quarter. Redmile Group LLC raised its holdings in shares of Scholar Rock by 0.3% in the first quarter. Redmile Group LLC now owns 6,419,610 shares of the company’s stock valued at $114,012,000 after acquiring an additional 17,105 shares in the last quarter. Vanguard Group Inc. increased its position in Scholar Rock by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 2,969,534 shares of the company’s stock valued at $52,739,000 after purchasing an additional 114,550 shares during the period. Bellevue Group AG lifted its position in shares of Scholar Rock by 1.5% in the 4th quarter. Bellevue Group AG now owns 2,168,925 shares of the company’s stock worth $40,776,000 after purchasing an additional 31,000 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Scholar Rock by 31.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,430,764 shares of the company’s stock valued at $26,898,000 after purchasing an additional 342,690 shares in the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on SRRK shares. Wedbush reissued an “outperform” rating and set a $23.00 price target on shares of Scholar Rock in a report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Scholar Rock in a report on Tuesday, June 25th. Finally, BMO Capital Markets upped their target price on shares of Scholar Rock from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Scholar Rock has an average rating of “Buy” and a consensus target price of $26.43.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.